




Instance: composition-en-3b1ab70efa7458a20495ebc38b1c3fc7
InstanceOf: CompositionUvEpi
Title: "Composition for ibandronic Package Leaflet"
Description:  "Composition for ibandronic Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp619337e5e016844decf29187faaa3bfc)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ibandronic"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What  Ibandronic Acid Teva is and what it is used for </li>
<li>What you need to know before you take Ibandronic Acid Teva </li>
<li>How to take Ibandronic Acid Teva </li>
<li>Possible side effects </li>
<li>How to store Ibandronic Acid Teva </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ibandronic is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ibandronic is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ibandronic Acid Teva contains the active substance ibandronic acid. This belongs to a group of 
medicines called bisphosphonates. </p>
<p>Ibandronic Acid Teva is used in adults and prescribed to you if you have breast cancer that has spread 
to your bones (called bone  metastases ). </p>
<ul>
<li>It helps to prevent your bones from breaking (fractures). </li>
<li>It also helps to prevent other bone problems that may need surgery or radiotherapy. </li>
</ul>
<p>Ibandronic Acid Teva works by reducing the amount of calcium that is lost from your bones. This 
helps to stop your bones from getting weaker. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ibandronic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ibandronic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Ibandronic Acid Teva 
* if you are allergic to ibandronic acid or any of the other ingredients of this medicine (listed in 
section 6) 
* if you have problems with your food pipe/gullet (oesophagus) such as narrowing or difficulty 
swallowing 
* if you cannot stand or sit upright for at least one hour (60 minutes) at a time 
* if you have or ever had low calcium in your blood. </p>
<p>Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or 
pharmacist before taking Ibandronic Acid Teva. </p>
<p>Warnings and precautions 
A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported very 
rarely in the post-marketing setting in patients receiving Ibandronic Acid Teva for cancer-related 
conditions. ONJ can also occur after stopping treatment. 
It is important to try and prevent ONJ developing as it is a painful condition that can be difficult to 
treat. In order to reduce the risk of developing osteonecrosis of the jaw, there are some precautions 
you should take. </p>
<p>Before receiving treatment, tell your doctor/nurse (health care professional) if:</p>
<ul>
<li>you have any problems with your mouth or teeth such as poor dental health, gum disease or a 
planned tooth extraction. </li>
<li>you do not receive routine dental care or have not had a dental check up for a long time. </li>
<li>you are a smoker (as this may increase the risk of dental problems). </li>
<li>you have previously been treated with a bisphosphonate (used to treat or prevent bone 
disorders). </li>
<li>you are taking medicines called corticosteroids (such as prednisolone or dexamethasone). </li>
<li>you have cancer. </li>
</ul>
<p>Your doctor may ask you to undergo a dental examination before starting treatment with Ibandronic 
Acid Teva. </p>
<p>While being treated, you should maintain good oral hygiene (including regular teeth brushing) and 
receive routine dental check-ups. If you wear dentures you should make sure these fit properly. If you 
are under dental treatment or will undergo dental surgery (e.g. tooth extractions), inform your doctor 
about your dental treatment and tell your dentist that you are being treated with Ibandronic Acid Teva. </p>
<p>Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth 
such as loose teeth, pain or swelling, non-healing of sores or discharge, as these could be signs of 
osteonecrosis of the jaw. </p>
<p>Talk to your doctor or pharmacist before taking Ibandronic Acid Teva: 
 - if you are allergic to any other bisphosphonates 
- if you have any swallowing or digestion problems 
- if you have high or low blood levels of vitamin D or any other minerals 
- if you have kidney problems. </p>
<p>Irritation, inflammation or ulceration of the gullet/food pipe (oesophagus) often with symptoms of 
severe pain in the chest, severe pain after swallowing food and/or drink, severe nausea, or vomiting 
may occur, especially if you do not drink a full glass of water and/or if you lie down within an hour of 
taking Ibandronic Acid Teva. If you develop these symptoms, stop taking Ibandronic Acid Teva and 
tell your doctor straight away (see sections 3 and 4). </p>
<p>Children and adolescents<br />
Ibandronic Acid Teva should not be used in children and adolescents below the age of 18 years. </p>
<p>Other medicines and Ibandronic Acid Teva 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This is because Ibandronic Acid Teva can affect the way some other medicines work. Also 
some other medicines can affect the way Ibandronic Acid Teva works. </p>
<p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p>
<ul>
<li>supplements containing calcium, magnesium, iron or aluminium </li>
<li>acetylsalicylic acid and non-steroidal anti-inflammatory medicines called  NSAIDs , such as 
ibuprofen or naproxen. This is because NSAIDs and Ibandronic Acid Teva can both irritate your 
stomach and gut </li>
<li>a type of antibiotic injection called  aminoglycoside  such as gentamicin. This is because 
aminoglycosides and Ibandronic Acid Teva can both lower the amount of calcium in your blood. </li>
</ul>
<p>Taking medicines that reduce stomach acid such as cimetidine and ranitidine, may slightly increase the 
effects of Ibandronic Acid Teva. 
Ibandronic Acid Teva with food and drink 
Do not take Ibandronic Acid Teva with food or any other drinks except water as Ibandronic Acid Teva 
is less effective if it is taken with food or drink (see section 3).  </p>
<p>Take Ibandronic Acid Teva with at least 6 hours after you had last had anything to eat, drink or any 
other medicines or supplements (e.g. products containing calcium (milk), aluminium, magnesium and 
iron) except water. After taking your tablet, wait at least 30 minutes. Then you can have your first 
food and drink, and take any medicines or supplements (see section 3). </p>
<p>Pregnancy and breast-feeding 
Do not take Ibandronic Acid Teva if you are pregnant, planning to get pregnant or if you are 
breast-feeding. Ask your doctor or pharmacist for advice before taking this medicine. </p>
<p>Driving and using machines 
You can drive and use machines as it s expected that Ibandronic Acid Teva has no or negligible effect 
on your ability to drive and use machines. Talk to your doctor first if you want to drive, use machine 
or tools. </p>
<p>Ibandronic Acid Teva contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say 
essentially  sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ibandronic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ibandronic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>Take your tablet at least 6 hours after you had last had anything to eat, drink or any other medicines or 
supplements except water. Water with a high concentration of calcium should not be used. If there is 
concern regarding potentially high levels of calcium in the tap water (hard water), it is advised to use 
bottled water with a low mineral content. </p>
<p>Your doctor may do regular blood tests while you are taking Ibandronic Acid Teva. This is to check 
that you are being given the right amount of medicine. </p>
<p>Taking this medicine 
It is important that you take Ibandronic Acid Teva at the right time and in the right way. This is 
because it can cause irritation, inflammation or ulcers in your food pipe/gullet (oesophagus). </p>
<p>You can help stop this happening by doing the following: </p>
<ul>
<li>
<p>Take your tablet as soon as you get up for the day before having your first food, drink, any 
medicine or supplements. </p>
</li>
<li>
<p>Take your tablet with a full glass of water only (about 200 mL). Do not take your tablet with 
any drink other than water. </p>
</li>
<li>
<p>Swallow the tablet whole. Do not chew, suck or crush the tablet. Do not let the tablet dissolve in 
your mouth. </p>
</li>
<li>
<p>After taking your tablet, wait at least 30 minutes. Then you can have your first food and drink, 
and take any medicines or supplements. </p>
</li>
<li>
<p>Stay upright (sitting or standing) while taking your tablet and for the next hour (60 minutes). 
Otherwise, some of the medicine could leak back into your food pipe/gullet (oesophagus). 
How much to take 
The usual dose of Ibandronic Acid Teva is one tablet each day. If you have moderate kidney problems, 
your doctor may reduce your dose to one tablet every other day. If you have severe kidney problems, 
your doctor may reduce your dose to one tablet each week. </p>
</li>
</ul>
<p>If you take more Ibandronic Acid Teva than you should 
If you take too many tablets talk to a doctor or go to hospital straight away. Drink a full glass of milk 
before you go. Do not make yourself sick. Do not lie down. </p>
<p>If you forget to take Ibandronic Acid Teva 
Do not take a double dose to make up for a forgotten dose. If you are taking a tablet each day, skip the 
missed dose completely. Then carry on as usual the next day. If you are taking a tablet every other day 
or once a week, ask your doctor or pharmacist for advice. </p>
<p>If you stop taking Ibandronic Acid Teva 
Keep taking Ibandronic Acid Teva for as long as your doctor tells you. This is because the medicine 
will only work if it is taken all the time. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Talk to a nurse or a doctor straight away if you notice any of the following serious side effects, 
you may need urgent medical treatment: </p>
<p>Common (may affect up to 1 in 10 people): 
* feeling sick, heartburn and discomfort in swallowing (inflammation of your gullet/food pipe) </p>
<p>Uncommon (may affect less than 1 in 100 people): 
* severe stomach pain. This could be a sign of an ulcer of the first section of the bowel (duodenum) 
that is bleeding, or that your stomach is inflamed (gastritis) </p>
<p>Rare (may affect up to 1 in 1,000 people): 
* persistent eye pain and inflammation 
* new pain, weakness or discomfort in your thigh, hip or groin. You may have early signs of a 
possible unusual fracture of the thigh bone. </p>
<p>Very rare (may affect up to 1 in 10,000 people): 
* pain or sore in your mouth or jaw. You may have early signs of severe jaw problems (necrosis 
[dead bone tissue] in the jaw bone). 
* Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. These 
could be signs of bone damage in the ear. 
* itching, swelling of your face, lips, tongue and throat, with difficulty breathing. You may be 
having a serious, potentially life threatening allergic reaction. 
* severe adverse skin reactions. </p>
<p>Not known (frequency cannot be estimated from the available data): 
* asthma attack </p>
<p>Other possible side effects </p>
<p>Common (may affect up to 1 in 10 people): 
* tummy pain, indigestion 
* low calcium levels in your blood 
* weakness. </p>
<p>Uncommon (may affect less than 1 in 100 people): 
* chest pain 
* itching or tingling skin (paraesthesia) 
* flu-like symptoms, feeling generally unwell or in pain 
* dry mouth, strange taste in your mouth or difficulty swallowing 
* anaemia(bloodlessness) 
* high levels of urea or high levels of parathyroid hormone in your blood. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ibandronic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ibandronic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The 
expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Ibandronic Acid Teva contains 
* The active substance is ibandronic acid. Each film-coated tablet contains 50 mg ibandronic acid 
(as sodium monohydrate). 
The other ingredients are: 
* tablet core: cellulose microcrystalline, povidone K-30, crospovidone (type A), silica colloidal 
anhydrous, stearic acid; 
* tablet coating: titanium dioxide (E 171), hypromellose, macrogol 400, polysorbate 80. What Ibandronic Acid Teva looks like and contents of the pack 
The Ibandronic Acid Teva film-coated tablets are white, biconvex, capsule-shaped, engraved  50  on 
one side and plain on the other. </p>
<p>Ibandronic Acid Teva comes in blisters (PVC/Aclar/PVC   Aluminium) in cartons of 28 or 84 tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Marketing Authorisation Holder: 
Teva B.V. 
Swensweg 5 
2031 GA Haarlem 
The Netherlands  </p>
<p>Manufacturer: 
Teva Pharmaceutical Works Private Limited Company 
Pallagi  t 13, 
4042 Debrecen 
Hungary </p>
<p>Pharmachemie B.V. 
Swensweg 5, 
2031 GA Haarlem 
The Netherlands </p>
<p>Teva Czech Industries s.r.o 
Ostravska 29/305, 
747 70 Opava-Komarov 
Czech Republic </p>
<p>Teva Operations Poland Sp.z.o.o 
ul. Mogilska 31-546 Krakow 
Poland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
T l/Tel: +32 38207Lietuva 
UAB Teva Baltics 
Tel: +370 52660  </p>
<p>Te : +359 24899Luxembourg/Luxemburg 
Teva Pharma Belgium N.V./S.A./AG 
Belgique/Belgien 
T l/Tel: +32 38207 esk  republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007Magyarorsz g 
Teva Gy gyszergy r Zrt. 
Tel: +36 12886Danmark 
Teva Denmark A/S 
Tlf: +45 44985Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407Deutschland 
TEVA GmbH 
Tel: +49 73140Nederland 
Teva Nederland B.V. 
Tel: +31 8000228Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610Norge 
Teva Norway AS 
Tlf: +47 66775<br />
Specifar A.B.E.E. 
 : +30 2118805 sterreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970Espa a 
Teva Pharma, S.L.U. 
Tel: +34 913873Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459France 
Teva Sant<br />
T l: +33 155917Portugal 
Teva Pharma - Produtos Farmac uticos, Lda. 
Tel: +351 214767Hrvatska 
Pliva Hrvatska d.o.o. 
Tel: +385 13720Rom nia 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 sland 
Teva Pharma Iceland ehf. 
S mi: +354 5503Slovensk  republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267Italia 
Teva Italia S.r.l. 
Tel: +39 028917Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805<br />
Specifar A.B.E.E. </p>
<p>: +30 2118805Sverige 
Teva Sweden AB 
Tel: +46 42121Latvija 
UAB Teva Baltics fili le Latvij<br />
Tel: +371 67323United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407This leaflet was last revised in {MM/YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-3b1ab70efa7458a20495ebc38b1c3fc7
InstanceOf: CompositionUvEpi
Title: "Composition for ibandronic Package Leaflet"
Description:  "Composition for ibandronic Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp619337e5e016844decf29187faaa3bfc)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ibandronic"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Ibandronsyre Teva </li>
<li>Sådan skal du tage Ibandronsyre Teva </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ibandronic is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ibandronic is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ibandronsyre Teva indeholder det aktive stof ibandronsyre, som tilhører en gruppe af lægemidler 
kaldet bisphosphonater. </p>
<p>Ibandronsyre Teva bruges til voksne og bliver ordineret til dig, hvis du har brystkræft, som har spredt 
sig til dine knogler (kaldet knoglemetastaser). </p>
<ul>
<li>
<p>Det hjælper med at forebygge knoglebrud </p>
</li>
<li>
<p>Det hjælper med at forebygge andre knogleproblemer, som kan kræve operation eller 
strålebehandling. </p>
</li>
</ul>
<p>Ibandronsyre Teva virker ved at nedsætte den mængde calcium, som mistes fra knoglerne. Det 
modvirker, at dine knogler bliver svagere. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ibandronic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ibandronic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Ibandronsyre Teva 
- hvis du er allergisk over for ibandronsyre eller et af de øvrige indholdsstoffer i Ibandronsyre 
Teva (angivet i punkt 6). 
- hvis du har visse problemer med spiserøret/mavesækken, såsom indsnævring eller synkebesvær 
- hvis du ikke kan stå eller sidde oprejst i mindst én time (60 minutter) ad gangen 
- hvis du har eller nogensinde har haft lavt calciumindhold i blodet. </p>
<p>Tag ikke denne medicin, hvis noget af ovenstående passer på dig. Hvis du er i tvivl, så kontakt lægen 
eller apotekspersonalet, før du begynder at tage Ibandronsyre Teva. </p>
<p>Advarsler og forsigtighedsregler 
En bivirkning kaldet knoglenekrose i kæben (skader på knoglen i kæben) er blevet rapporteret meget 
sjældent i post-marketing perioden hos patienter ved behandling med Ibandronsyre Teva for kræft-
relateret forhold. Knoglenekrose i kæben kan også forekomme efter behandlingen med Ibandronsyre 
Teva er stoppet. </p>
<p>Det er vigtigt at forsøge at forhindre knoglenekrose i kæben i at udvikle sig, da det er en smertefuld 
tilstand, som kan være vanskelig at behandle. For at reducere risikoen for at udvikle knoglenekrose i 
kæben, er der nogle forholdsregler du bør tage. </p>
<p>Før du modtager behandlingen, fortæl din læge eller sygeplejerske (sundhedsperson), hvis:</p>
<ul>
<li>du har problemer med din mund og tænder, såsom dårlig mundhygiejne, tandkødssygdom eller 
en planlagt tandudtrækning </li>
<li>du ikke modtager regelmæssig tandpleje eller ikke har været til kontrol i lang tid </li>
<li>du er ryger (dette kan øge risikoen for tandproblemer) </li>
<li>du tidligere har været i behandling med bisphosphat (anvendes til at behandle eller forbygge 
knoglelidelser) </li>
<li>du tager steroider (såsom prednisolon eller dexamethason) </li>
<li>du har kræft </li>
</ul>
<p>Din læge kan bede dig om at gennemgå et tandeftersyn før du starter med Ibandronsyre Teva-
behandling. </p>
<p>Mens du er i behandling bør du opretholde en god mundhygiejne (herunder regelmæssig 
tandbørstning) og få foretaget rutinemæssig tandeftersyn. Hvis du bruger proteser bør du sørge for, at 
de passer ordentligt. Informer din læge, hvis du er i gang med en tandbehandling eller vil få foretaget 
en tandoperation (f.eks. tandudtrækning), og fortæl ligeledes din tandlæge, at du er i behandling med 
Ibandronsyre Teva. </p>
<p>Kontakt straks din læge og tandlæge, hvis du oplever problemer med din mund eller tænder såsom 
løse tænder, smerter eller hævelser eller hvis dine sår væsker og/eller ikke heler, da dette kan være 
tegn på knoglenekrose i kæben. </p>
<p>Kontakt lægen eller apotekspersonalet, før du tager Ibandronsyre Teva:</p>
<ul>
<li>hvis du er allergisk over for andre bisphosphonater </li>
<li>hvis du har synkebesvær eller fordøjelsesbesvær </li>
<li>hvis du har forhøjet eller nedsat indhold af vitamin D eller andre mineraler i blodet </li>
<li>hvis du har problemer med nyrerne. </li>
</ul>
<p>Der kan forekomme irritation, inflammation (betændelseslignende tilstand) eller sårdannelse i 
spiserøret, ofte med symptomer som stærk smerte i brystet, stærk smerte efter at have sunket mad 
og/eller drikke, voldsom kvalme eller opkastning, især hvis du ikke drikker et helt glas almindeligt 
vand, og/eller hvis du ligger ned inden for én time efter, du har taget Ibandronsyre Teva. Hvis du 
udvikler disse symptomer, skal du stoppe med at tage Ibandronsyre Teva og straks kontakte din læge 
(se punkt 3 og 4). </p>
<p>Børn og unge 
Ibandronsyre Teva må ikke anvendes til børn og unge under 18 år. </p>
<p>Brug af anden medicin sammen med Ibandronsyre Teva 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin. Dette skyldes, at Ibandronsyre Teva kan påvirke den 
måde anden medicin virker på, ligesom anden medicin kan påvirke den måde, hvorpå Ibandronsyre 
Teva virker. </p>
<p>Fortæl især din læge eller apotekspersonalet, hvis du tager noget af nedenstående medicin: </p>
<ul>
<li>
<p>kosttilskud indeholdende calcium, magnesium, jern eller aluminium </p>
</li>
<li>
<p>acetylsalicylsyre, non-steroide anti-inflammatoriske lægemidler kaldet NSAIDer, såsom 
ibuprofen eller naproxen. Det er fordi NSAIDer og Ibandronsyre Teva begge kan irritere din 
mave-tarmkanal </p>
</li>
<li>
<p>injektioner af en type antibiotika, der kaldes "aminoglykosider" såsom gentamicin. 
Aminoglykosider og Ibandronsyre Teva kan begge nedsætte mængden af calcium i dit blod.  </p>
</li>
</ul>
<p>Indtagelse af medicin, som reducerer mængden af mavesyre, såsom cimetidin og ranitidin, kan give let 
forøget effekt af Ibandronsyre Teva. </p>
<p>Brug af Ibandronsyre Teva sammen med mad og drikke 
Tag ikke Ibandronsyre Teva sammen med mad eller andre drikkevarer end vand, da Ibandronsyre 
Teva virker mindre effektivt, hvis det tages sammen med mad og drikke (se punkt 3). </p>
<p>Indtag Ibandronsyre Teva mindst 6 timer efter, at du sidst har spist, drukket eller taget nogen form for 
anden medicin, vitaminer og mineraler eller kosttilskud (f.eks. produkter, der indeholder kalk (mælk), 
aluminium, magnesium og jern) andet end vand. Efter indtagelse af tabletten skal du vente mindst minutter, før du indtager mad, drikke, anden medicin, vitaminer og mineraler eller kosttilskud (se 
punkt 3). </p>
<p>Graviditet og amning 
Tag ikke Ibandronsyre Teva, hvis du er gravid eller planlægger at blive gravid, eller hvis du ammer. 
Spørg lægen eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
Du kan føre motorkøretøj og betjene maskiner, da det forventes, at Ibandronsyre Teva ikke eller kun i 
ubetydelig grad påvirker din evne til at føre motorkøretøj og betjene maskiner. Kontakt først lægen, 
hvis du vil føre motorkøretøj, betjene maskiner eller værktøj. </p>
<p>Ibandronsyre Teva indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. filmovertrukket tablet, dvs. det 
er i det væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ibandronic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ibandronic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet.  </p>
<p>Indtag Ibandronsyre Teva mindst 6 timer efter, at du sidst har spist, drukket eller taget nogen form for 
anden medicin, vitaminer og mineraler eller kosttilskud andet end vand. Vand med et højt kalkindhold 
bør ikke bruges. Hvis der er usikkerhed omkring et eventuelt for højt kalkindhold i postevandet, 
anbefales det at bruge vand på flaske med et lavt mineralindhold. </p>
<p>Din læge kan vælge at tage regelmæssige blodprøver, mens du er i behandling med Ibandronsyre 
Teva. Dette er for at undersøge, om du får den rigtige mængde medicin. </p>
<p>Når du tager denne medicin 
Det er vigtigt, at du tager Ibandronsyre Teva på det rigtige tidspunkt og på den rigtige måde. Det er 
fordi, der kan forekomme irritation, betændelse eller sårdannelse i spiserøret/mavesækken. </p>
<p>Du kan mindske risikoen for at dette forekommer ved at gøre følgende:   </p>
<ul>
<li>
<p>Tag din tablet så snart du står op om morgenen, før du spiser noget, drikker noget eller tager 
nogen form for medicin, vitaminer og mineraler eller kosttilskud.  </p>
</li>
<li>
<p>Tag din Ibandronsyre Teva-tablet udelukkende med et helt glas vand (ca. 200 ml).  </p>
</li>
<li>
<p>Tag ikke tabletten med andet end almindeligt vand.  </p>
</li>
<li>
<p>Synk tablettten hel. Lad være med at tygge, sutte, eller knuse tabletten. Lad ikke tabletten 
opløses i munden </p>
</li>
<li>
<p>Efter indtagelse af Ibandronsyre Teva-tabletten skal du vente i mindst 30 minutter.Derefter 
kan du indtage dagens første mad og drikke samt tage medicin, vitaminer og mineraler eller 
kosttilskud. </p>
</li>
<li>
<p>Du skal indtage indtage tabletten i oprejst stilling (siddende eller stående) og forblive oprejst i 
den næste time (60 minutter) efter, at du har taget din tablet. Hvis du ikke forbliver oprejst 
(siddende eller liggende), kan noget af medicinen løbe tilbage i spiserøret. </p>
</li>
</ul>
<p>Hvor meget skal du tage 
Den sædvanlige dosis Ibandronsyre Teva er én tablet dagligt. Hvis du lider af nyreproblemer, kan din 
læge vælge at nedsætte dosis til én tablet hver anden dag (i tilfælde af moderat nyresygdom) eller til én 
tablet om ugen (i tilfælde af alvorlig nyresygdom). </p>
<p>Hvis du har taget for meget Ibandronsyre Teva 
Kontakt straks lægen eller tag på skadestuen med det samme, hvis du har indtaget for mange tabletter. 
Drik et helt glas mælk inden du kører. Fremkald ikke opkastning, og læg dig ikke ned.  </p>
<p>Hvis du har glemt at tage Ibandronsyre Teva 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. Hvis du tager én tablet hver dag, 
spring da den glemte tablet over og fortsæt som normalt den næste dag. Hvis du tager én tablet hver 
anden dag eller én gang om ugen, spørg da din læge eller apotekspersonalet til råds. </p>
<p>Hvis du holder op med at tage Ibandronsyre Teva 
Det er vigtigt, at du anvender Ibandronsyre Teva så længe, din læge har ordineret det. Ibandronsyre 
Teva kan kun afhjælpe din tilstand så længe, du fortsætter med at anvende det </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Kontakt straks sygeplejersken eller lægen, hvis du oplever nogle af følgende alvorlige 
bivirkninger - du kan have brug for akut lægehjælp: </p>
<p>Almindelig (kan forekomme hos 1 ud af 10 behandlede) 
• kvalme, halsbrand eller ubehag ved at synke (betændelse i spiserøret) </p>
<p>Ikke almindelig (kan forekomme hos 1 ud af 100 behandlede) 
• stærke mavesmerter. Dette kan være tegn på, at du har et blødende sår i den første del af tarmen 
(tolvfingertarmen), eller at mavens slimhinde er betændt (gastritis). </p>
<p>Sjælden (kan forekomme hos 1 ud af 1.000 behandlede) 
• vedvarende smerte og betændelse i øjet. 
• ny smerte, svækkelse eller ubehag i dine lår, hofte eller lyske. Du kan have tidlige tegn på et 
brud på lårbensknoglen. </p>
<p>Meget sjælden (kan forekomme hos 1 ud af 10.000 behandlede) 
• smerte eller ømhed i munden eller kæben. Det kan være tegn på skader på knoglen i kæben 
(knoglenekrose [dødt knoglevæv]). 
• tal med din læge, hvis du har ørepine, udflåd fra øret og/eller øreinfektion. Det kan være tegn på 
skader på knoglerne i øret. 
• kløe, hævelse af ansigt, læber, tunge og hals, med vejrtrækningsproblemer. Du kan have fået 
en alvorlig allergisk reaktion, som kan være livstruende. 
• svære hudreaktioner </p>
<p>Ikke kendt (hyppigheden kan ikke vurderes ud fra tilgængelige data) 
• astmaanfald </p>
<p>Andre bivirkninger </p>
<p>Almindelig (kan forekomme hos 1 ud af 10 behandlede): 
• mavesmerter, fordøjelsesbesvær 
• lavt indhold af kalk i blodet 
• svaghedsfølelse </p>
<p>Ikke almindelig (kan forekomme hos færre end 1 ud af 100 behandlede): 
• brystsmerter 
• kløe eller prikken i huden 
• influenzalignende symptomer, følelse af utilpashed eller smerte 
• mundtørhed, mærkelig smag i munden eller synkebesvær 
• blodmangel 
• forhøjet koncentration i blodet af urinsyre eller hormoner fra biskjoldbruskkirtlen </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ibandronic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ibandronic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisteren og æsken efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ibandronsyre Teva indeholder: </p>
<ul>
<li>
<p>Aktivt stof: ibandronsyre. Hver filmovertrukket tablet indeholder 50 mg ibandronsyre (som 
natrium monohydrat). 
Øvrige indholdsstoffer: </p>
</li>
<li>
<p>tabletkerne: mikrokrystallinsk cellulose, povidon K-30, crospovidon (type A), kolloid vandfri 
silica, stearinsyre. </p>
</li>
<li>
<p>tabletovertræk: titandioxid (E171), hypromellose, macrogol 400, polysorbat 80. Udseende og pakningsstørrelser 
Ibandronsyre Teva filmovertrukne tabletter er hvide, bikonvekse, kapselformede, præget med “50" på 
den ene side og ingenting på den anden side. </p>
</li>
</ul>
<p>Ibandronsyre Teva findes i blistere (PVC/Aclar/PVC - Aluminium) i æsker á 28 eller 84 tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen: 
Teva B.V. 
Swensweg 5 
2031 GA Haarlem 
Holland </p>
<p>Fremstiller: 
Teva Pharmaceutical Works Private Limited Company 
Pallagi út 13<br />
4042 Debrecen 
Ungarn </p>
<p>Pharmachemie B.V. 
Swensweg 5<br />
2031 GA Haarlem 
Holland </p>
<p>Teva Czech Industries s.r.o 
Ostravska 29/305<br />
747 70 Opava-Komarov 
Tjekkiet </p>
<p>Teva Operations Poland Sp.z o.o 
ul. Mogilska 31-546 Krakow 
Polen </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
Tél/Tel: +32 38207 
Lietuva 
UAB Teva Baltics 
Tel: +370 52660 
България 
Тева Фарма ЕАД 
Teл: +359 24899 
Luxembourg/Luxemburg 
Teva Pharma Belgium N.V./S.A./AG 
Belgique/Belgien 
Tél/Tel: +32 38207 
Česká republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007 
Magyarország 
Teva Gyógyszergyár Zrt. 
Tel: +36 12886 
Danmark 
Teva Denmark A/S 
Tlf: +45 44985 
Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407 
Deutschland 
TEVA GmbH 
Tel: +49 73140 
Nederland 
Teva Nederland B.V. 
Tel: +31 8000228 
Eesti 
UAB Teva Baltics Eesti filiaal 
Norge 
Teva Norway AS 
Tel: +372 6610 
Tlf: +47 66775 
Ελλάδα 
Specifar A.B.E.E. 
Τηλ: +30 2118805 
Österreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970 
España 
Teva Pharma, S.L.U. 
Tel: +34 913873 
Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459 
France 
Teva Santé 
Tél: +33 155917 
Portugal 
Teva Pharma - Produtos Farmacêuticos, Lda. 
Tel: +351 214767 
Hrvatska 
Pliva Hrvatska d.o.o. 
Tel: +385 13720 
România 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306 
Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407 
Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 
Ísland 
Teva Pharma Iceland ehf. 
Sími: +354 5503 
Slovenská republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267 
Italia 
Teva Italia S.r.l. 
Tel: +39 028917 
Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805 
Κύπρος 
Specifar A.B.E.E. 
Ελλάδα 
Τηλ: +30 2118805 
Sverige 
Teva Sweden AB 
Tel: +46 42121 
Latvija 
UAB Teva Baltics filiāle Latvijā 
Tel: +371 67323 
United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407 </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ} </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. 
Indlægsseddel: Information til patienten </p>
<p>Ibandronsyre Teva 150 mg filmovertrukne tabletter 
ibandronsyre </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. 
- Gem indlægssedlen. Du kan få brug for at læse den igen. 
- Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. 
- Lægen har ordineret dette lægemiddel til dig personligt. Lad derfor være med at give medicinen 
til andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har. 
- Kontakt lægen eller apotekspersonalet, hvis du får bivirkninger, herunder bivirkninger, som 
ikke er nævnt i denne indlægsseddel. Se punkt 4. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-3b1ab70efa7458a20495ebc38b1c3fc7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ibandronic Package Leaflet for language en"
Description: "ePI document Bundle for ibandronic Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-3b1ab70efa7458a20495ebc38b1c3fc7"
* entry[0].resource = composition-en-3b1ab70efa7458a20495ebc38b1c3fc7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3b1ab70efa7458a20495ebc38b1c3fc7"
* entry[=].resource = mp3b1ab70efa7458a20495ebc38b1c3fc7
                            
                    
Instance: bundlepackageleaflet-da-3b1ab70efa7458a20495ebc38b1c3fc7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ibandronic Package Leaflet for language da"
Description: "ePI document Bundle for ibandronic Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-3b1ab70efa7458a20495ebc38b1c3fc7"
* entry[0].resource = composition-da-3b1ab70efa7458a20495ebc38b1c3fc7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3b1ab70efa7458a20495ebc38b1c3fc7"
* entry[=].resource = mp3b1ab70efa7458a20495ebc38b1c3fc7
                            
                    



Instance: mp3b1ab70efa7458a20495ebc38b1c3fc7
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product ibandronic"
Description: "ibandronic"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/10/642/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Ibandronic Acid Teva is indicated in adults for the prevention of skeletal events (pathological"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "ibandronic"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 3b1ab70efa7458a20495ebc38b1c3fc7ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "ibandronic"

* status = #current
* mode = #working

* title = "List of all ePIs associated with ibandronic"

* subject = Reference(mp619337e5e016844decf29187faaa3bfc)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#ibandronic "ibandronic"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-3b1ab70efa7458a20495ebc38b1c3fc7) // ibandronic en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-3b1ab70efa7458a20495ebc38b1c3fc7) // ibandronic da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-3b1ab70efa7458a20495ebc38b1c3fc7
InstanceOf: List

* insert 3b1ab70efa7458a20495ebc38b1c3fc7ListRuleset
    